Molecular biological analysis of the heterogeneous prostate cancer group Gleason score 7.
BACKGROUND
On the basis of a multicolor-FISH test we aimed at verifying whether there is any molecular biological background for the different behavior of Gleason Score 7 prostate cancer (PCa).


METHODS
Biopsies of 44 patients with histological verified PCa, 20 with Gleason score 3 + 4 (group A) and 24 with 4 + 3 (group B), were analyzed using FISH.


RESULTS
In group A, FISH detected a unique gain of 8q24 in 2 patients (10.0%) and a unique loss of 8p22 in 9 patients (45.0%). No concurrent loss and gain of both sites were found in this group. Of group B (4 + 3) a unique loss of 8p22 was observed in 14 patients (58.3%) and a concurrent loss of 8p22 and gain of 8q24 in 6 patients (25.0%).


CONCLUSIONS
Different molecular genetic patterns could explain the different biological behavior of the 2 groups. The analysis of chromosomal aberrations could therefore influence the clinical decision process in the future.
Mian
Christine
C
Department of Pathology, Central Hospital of Bolzano, Italy. chmian@libero.it
Lodde
Michele
M
Comploj
Evi
E
Palermo
Salvatore
S
Lusuardi
Lukas
L
Marziani
Fiovo
F
Chiocchetti
Andreas
A
Spada
Alessandra
A
Mian
Michael
M
Pycha
Armin
A
D000368:Aged; D000369:Aged, 80 and over; D001706:Biopsy; D002869:Chromosome Aberrations; D002898:Chromosomes, Human, Pair 8 / Q000235:genetics; D004273:DNA, Neoplasm / Q000032:analysis / Q000235:genetics; D018450:Disease Progression; D018740:Genetic Heterogeneity; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000235:genetics* / Q000473:pathology*; D012720:Severity of Illness Index
D004273:DNA, Neoplasm